Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1
Frédéric Lavainne(Inserm), Fádi Fakhouri(University Hospital of Lausanne), Mélanie Néel(Inserm), Alan D. Salama(The Royal Free Hospital), Ruth J. Pepper(University College Hospital), Emmanuelle Meffray(Inserm), Catherine Delcroix(Centre Hospitalier Universitaire de Nantes)
Cited by 14
Related Papers
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156
Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production
|Lara D. Veeken|2008|149